Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.

Journal Article (Clinical Trial;Journal Article)

We hypothesized that third-party fecal microbiota transplantation (FMT) may restore intestinal microbiome diversity after allogeneic hematopoietic cell transplantation (allo-HCT). In this open-label single-group pilot study, 18 subjects were enrolled before allo-HCT and planned to receive third-party FMT capsules. FMT capsules were administered no later than 4 weeks after neutrophil engraftment, and antibiotics were not allowed within 48 hours before FMT. Five patients did not receive FMT because of the development of early acute gastrointestinal (GI) graft-versus-host disease (GVHD) before FMT (n = 3), persistent HCT-associated GI toxicity (n = 1), or patient decision (n = 1). Thirteen patients received FMT at a median of 27 days (range, 19-45 days) after HCT. Participants were able to swallow and tolerate all FMT capsules, meeting the primary study endpoint of feasibility. FMT was tolerated well, with 1 treatment-related significant adverse event (abdominal pain). Two patients subsequently developed acute GI GVHD, with 1 patient also having concurrent bacteremia. No additional cases of bacteremia occurred. Median follow-up for survivors is 15 months (range, 13-20 months). The Kaplan-Meier estimates for 12-month overall survival and progression-free survival after FMT were 85% (95% confidence interval, 51%-96%) and 85% (95% confidence interval, 51%-96%), respectively. There was 1 nonrelapse death resulting from acute GI GVHD (12-month nonrelapse mortality, 8%; 95% confidence interval, 0%-30%). Analysis of stool composition and urine 3-indoxyl sulfate concentration indicated improvement in intestinal microbiome diversity after FMT that was associated with expansion of stool-donor taxa. These results indicate that empiric third-party FMT after allo-HCT appears to be feasible, safe, and associated with expansion of recipient microbiome diversity. This trial was registered at as #NCT02733744.

Full Text

Duke Authors

Cited Authors

  • DeFilipp, Z; Peled, JU; Li, S; Mahabamunuge, J; Dagher, Z; Slingerland, AE; Del Rio, C; Valles, B; Kempner, ME; Smith, M; Brown, J; Dey, BR; El-Jawahri, A; McAfee, SL; Spitzer, TR; Ballen, KK; Sung, AD; Dalton, TE; Messina, JA; Dettmer, K; Liebisch, G; Oefner, P; Taur, Y; Pamer, EG; Holler, E; Mansour, MK; van den Brink, MRM; Hohmann, E; Jenq, RR; Chen, Y-B

Published Date

  • April 10, 2018

Published In

  • Blood Adv

Volume / Issue

  • 2 / 7

Start / End Page

  • 745 - 753

PubMed ID

  • 29592876

Pubmed Central ID

  • PMC5894265

Electronic International Standard Serial Number (EISSN)

  • 2473-9537

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2018017731


  • eng

Conference Location

  • United States